Abstract:Introduction and Objectives: Gastric and pancreatic cancers lack effective therapies, leading to low survival rates particularly in the metastatic setting. Fibroblast growth factor receptor 2 (FGFR2) amplification and fusions with TACC2 appear in 5.5% and 2.1% of gastric tumors, respectively. In pancreatic cancers, the KRAS p.G12C mutation is limited to 1-2% of cases. FDA has recently approved drugs targeting both alterations, pemigatinib and infigratinib for cholangiocarcinoma with FGFR2 fusions; sotorasib and adagrasib for KRAS p.G12C mutant lung cancers. Here, we report the initiation of primary cultures that can be used as preclinical models for testing antitumor agents in gastric and pancreatic tumor cells. Materials and Methods: Pleural effusions were collected from a gastric and a pancreatic cancer patient, both metastatic. Cells were isolated by centrifugation, cultured for 2-3 months in complete medium and genotyped using next generation sequencing (NGS) and RNA nCounter hybridization. Primary cultures were treated with specific drugs depending on their molecular alterations and clinical guidelines. Cell viability was determined by MTT. Results: Tumor cells from the pleural effusion of the gastric cancer patient were grown in suspension. NGS and nCounter revealed a FGFR2-TACC2 fusion, a FGFR2 amplification (160 copies) and a TP53 p.G245S mutation (100% variant allele fraction, VAF). The fusion and the amplification were confirmed by FISH. Cells were sensitive to erdafitinib, with IC50=40 nM in MTT assays. Irinotecan, 5-fluorouracil and cisplatin were also tested; IC50 were below the described plasma Cmax in the first two cases. The patient was treated with first-line fluoropyrimidine and oxaliplatin with partial response and a 5-month progression-free survival. Due to rapid deterioration, 2nd line treatment was not administered. The tumor cells from the pancreatic cancer patient were adherent, NGS revealed a KRAS amplification (9 copies) accompanied by a KRAS p.G12C mutation (81% VAF) and a TP53 p.R175H mutation (99% VAF). MTT assays were performed to determine the cells' response to oxaliplatin, 5-fluorouracil, irinotecan, gemcitabine, nab-paclitaxel, adagrasib and sotorasib. IC50s below plasma Cmax were found in the last three cases. Remarkably, the IC50 for sotorasib was 100 nM and for adagrasib was 300 nM. The patient was treated with first-line gemcitabine and nab-paclitaxel with partial response but discontinued after three months due to hematological toxicity. Conclusions: Primary cultures can be initiated from malignant pleural effusions and used for genetic characterization and drug sensitivity profiling. Primaries with specific alterations can be employed as preclinical models to test targeted therapies. Citation Format: Silvia Garcia-Roman, Ekaterina Meshoulam Nikolaeva, Juan José García Mosquera, Mónica Garzón Ibáñez, Ruth Roman, Sonia Rodríguez, Cristina Rodríguez, Clara Mayo de las Casas, Rafael Rosell, Miguel A. Molina-Vila, Cristina Aguado Esteban. Molecular characterization and drug sensitivity of a gastric FGFR2-TACC2 and a pancreatic KRAS p.G12C primary culture [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6497.

FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer

Ductal pancreatic cancer interception by FGFR2 abrogation

FGFR2 Alteration As a Potential Therapeutic Target in Poorly Cohesive Gastric Carcinoma

N of 1 Case Reports of Exceptional Responders Accrued from Pancreatic Cancer Patients Enrolled in First-in-man Studies from 2002 Through 2012

Fusion genes in pancreatic tumors

Data from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers

Antitumor Effect of FGFR Inhibitors on a Novel Cholangiocarcinoma Patient Derived Xenograft Mouse Model Endogenously Expressing an FGFR2-CCDC6 Fusion Protein.

A phase II telemedicine study of pemigatinib in adult patients with unresectable or metastatic pancreas cancer with FGFR2 gene fusions or other FGFR genetic alterations.

Predictive Biomarkers and Personalized Medicine FGFR 2 Gene Ampli fi cation in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD 4547

FGFR2-TSC22D1, a Novel FGFR2 Fusion Gene Identified in a Patient with Colorectal Cancer: A Case Report.

Fgfr2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective Fgfr Inhibitor Azd4547

Abstract 6199: Fusion Genes: Novel Therapeutic Targets for Gastric Signet Ring Cell Carcinoma

Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series

Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

Incidence of FGFR-TACC Gene Fusions in Chinese Non-Small Cell Lung Cancer (NSCLC): A Multicenter Study.

Abstract 1968: Discovery of a highly potent and selective FGFR2 inhibitor for FGFR2-driven cancers

Abstract 880: Identifying ANKRD22 and fostamatinib as a theragnostic target and drug candidate for metastatic pancreatic cancer through in silico analysis

Abstract 6497: Molecular characterization and drug sensitivity of a gastric FGFR2-TACC2 and a pancreatic KRAS p.G12C primary culture